Hepatorenal syndrome

Reading File

Finding Sources

Searching PubMed

"hepatorenal syndrome"[MeSH Terms] AND treatment

Reading File

Loading Image

Reading File

I now have comprehensive information from multiple authoritative textbooks. Let me compile the full answer.

Hepatorenal Syndrome (HRS)

Definition

Hepatorenal syndrome is a form of functional renal failure - the kidneys are structurally normal but develop profound vasoconstriction - occurring in patients with advanced cirrhosis, acute liver failure, or alcoholic hepatitis. Histologically the kidneys show no intrinsic pathology; this is confirmed by the fact that kidneys transplanted from HRS patients into non-cirrhotic recipients recover normal function. - Sleisenger and Fordtran's Gastrointestinal and Liver Disease, p. 1817

HRS occurs in ~10-30% of hospitalized cirrhotic patients with ascites, with an annual incidence of roughly 8% in cirrhotic patients with ascites (some reports up to 40%). It develops in approximately 30% of cirrhotics admitted with SBP, 25% with severe alcoholic hepatitis, and 10% requiring serial large-volume paracenteses. - Sleisenger & Fordtran, p. 1817

Classification (Updated Nomenclature)

Old Term	New Term	Characteristics
Type 1 HRS	HRS-AKI	Rapidly progressive (over 1-2 weeks); ≥50% rise in creatinine or ≥0.3 mg/dL rise in 48h; Stage 2 or 3 AKI; worse prognosis
Type 2 HRS	HRS-CKD (or HRS-NAKI)	Gradual course; stable but elevated creatinine; associated with diuretic-resistant ascites; relatively better outcome

The updated International Club of Ascites (ICA) 2015 terminology replaced the old "type 1/type 2" distinction to align with general AKI staging frameworks. - Harrison's Principles of Internal Medicine 22E, p. 1378

Pathophysiology

The three key components that drive HRS (see diagram below):

1. Splanchnic and systemic arterial vasodilation Portal hypertension in cirrhosis leads to release of vasoactive substances - nitric oxide (NO), carbon monoxide, glucagon, prostacyclin, adrenomedullin, and endogenous opiates - causing progressive splanchnic and systemic vasodilation. This decreases effective circulating blood volume and blood pressure. Early on, increased cardiac output compensates (hyperdynamic circulation), but this becomes insufficient over time.

2. Compensatory renal vasoconstriction To maintain perfusion pressure, the body activates:

Sympathetic nervous system (SNS)
Renin-angiotensin-aldosterone system (RAAS)
Non-osmotic release of arginine vasopressin (ADH)
Intrarenal mediators (endothelins, altered prostaglandins, kallikreins)

The resulting intense renal vasoconstriction reduces renal perfusion and GFR. Eventually, tubular damage can occur - HRS can transition from a functional syndrome to organic disease.

3. Cardiac dysfunction (cirrhotic cardiomyopathy - CCM) Cirrhotic cardiomyopathy with reduced cardiac output is an additional contributing factor - patients who develop HRS have lower cardiac output than those who do not. - Sleisenger & Fordtran, p. 1818

Precipitating triggers include: diarrhea, diuretic overuse, GI bleeding, large-volume paracentesis without albumin, SBP/sepsis, and hepatic decompensation.

Diagnostic Criteria (ICA 2015)

All of the following must be present (Box 94.2):

Cirrhosis with ascites
AKI by ICA criteria:
- Rise in serum creatinine ≥0.3 mg/dL within 48 hours, OR
- ≥50% rise from baseline within 7 days
No response to 48 hours of diuretic withdrawal + IV albumin (1 g/kg/day, max 100 g/day)
Absence of shock
No recent nephrotoxic agents (NSAIDs, aminoglycosides, contrast)
No intrinsic renal disease - proteinuria <500 mg/day, no microhematuria (>50 RBC/HPF), normal renal ultrasound

- Sleisenger & Fordtran, p. 1819

AKI Staging (ICA):

Stage 1: creatinine rise ≥0.3 mg/dL or 1.5-2x baseline
Stage 2: creatinine rise >2-3x baseline
Stage 3: creatinine rise >3x baseline or creatinine ≥4 mg/dL with acute rise ≥0.3 mg/dL, or initiation of RRT

Urinary findings: Urine Na <10 mmol/L, urine osmolality > plasma osmolality (tubular function preserved). Oliguria is NOT used as a criterion because cirrhotic patients are frequently oliguric at baseline. - Sabiston Textbook of Surgery, p. 943

Important note on creatinine: Patients with advanced cirrhosis often have reduced muscle mass and impaired urea synthesis, causing artificially low baseline creatinine - even a small rise should prompt concern.

Differential Diagnosis of AKI in Cirrhosis

Must exclude before diagnosing HRS:

Pre-renal: GI hemorrhage, overdiuresis, diarrhea, lactulose overdose
Intrinsic renal: Acute tubular necrosis (ATN), acute interstitial nephritis, glomerulonephritis
Drug-induced: NSAIDs (renal vasoconstriction), aminoglycosides (nephrotoxic), ACE inhibitors, ARBs
Obstructive: Obstruction
Sepsis: SBP, other infections (must treat before diagnosing HRS)
Large-volume paracentesis without albumin replacement

Urinary biomarkers such as IL-18, NGAL (neutrophil gelatinase-associated lipocalin), urinary EGF, and FABP2 can help distinguish ATN from HRS (ATN typically shows higher NGAL).

Treatment

Step 1: Remove precipitants

Stop diuretics, NSAIDs, ACE inhibitors, ARBs, nephrotoxins
Treat infections (SBP, sepsis)

Step 2: Volume expansion

IV albumin 1 g/kg/day (max 100 g/day) for 48 hours - mandatory before diagnosing HRS

Step 3: Vasoconstrictors (for HRS-AKI)

Drug	Role	Notes
Terlipressin	First-line	Vasopressin analogue, 0.5-2.0 mg IV every 4-6 hours; FDA-approved in USA after CONFIRM trial; continued up to 14 days after creatinine returns to baseline
Norepinephrine	Second-line (ICU)	Low-dose; requires intensive monitoring
Midodrine + Octreotide + Albumin	Third-line (USA)	Alpha-agonist + somatostatin analogue; now considered inferior to terlipressin

The CONFIRM trial (phase III RCT) confirmed terlipressin + albumin leads to higher HRS reversal rates vs. placebo, leading to FDA approval. However, terlipressin carries risk of respiratory failure (ischemic adverse effects) and must be used with caution in patients with baseline pulmonary compromise. - Sabiston Textbook of Surgery, p. 944; Goldman-Cecil Medicine, p. 49

Step 4: Renal replacement therapy If pharmacologic treatment fails, RRT (dialysis) can be initiated as a bridge.

Step 5: Definitive therapy - Liver transplantation The only curative treatment. Renal function typically recovers after liver transplantation. HRS represents a priority indication for transplant listing. - Harrison's 22E, p. 1380

TIPS (transjugular intrahepatic portosystemic shunt) can be used as a bridge in some patients.

Prevention

Albumin infusion with large-volume paracentesis (1.5 g albumin per liter of ascites removed)
Albumin + antibiotics in SBP (1.5 g/kg on day 1, 1 g/kg on day 3 - reduces HRS incidence and improves survival)
Avoidance of nephrotoxins in cirrhotic patients
Primary and secondary prophylaxis of variceal bleeding
Quinolone prophylaxis after a first SBP episode

Prognosis

HRS-AKI carries very high in-hospital mortality without treatment
Median survival without treatment: weeks to months
Recovery of renal function is typical following liver transplantation
In patients with either HRS-AKI or HRS-CKD, prognosis is poor without transplantation - Harrison's 22E, p. 1380

Recent Evidence (2024-2026)

Two recent meta-analyses support current practice:

Terlipressin meta-analysis (Braga et al., 2025) - Confirmed terlipressin's superiority for HRS reversal in a meta-analysis of RCTs (PMID 40207491).
Adverse events of terlipressin (Shang et al., 2024) - Systematic review characterizing adverse events including respiratory complications (PMID 39298544).
Living-donor liver transplant in HRS (Viana et al., 2025) - Meta-analysis showing acceptable outcomes with living-donor LT in HRS patients (PMID 41118136).

Sources: Harrison's Principles of Internal Medicine 22E (2025) | Sleisenger & Fordtran's GI and Liver Disease | Goldman-Cecil Medicine | Sabiston Textbook of Surgery 14e | ICA Consensus Criteria (2015)

This is a shared conversation. Sign in to Orris to start your own chat.